

JAN 07 2009

FAX TRANSMISSION**DATE:** January 7, 2009**PTO IDENTIFIER:** Application Number 10/800,350
Patent Number**Inventor:** Krasnoperov et al.**MESSAGE TO:** US Patent and Trademark Office**FAX NUMBER:** (571) 273-8300**FROM:** ROPES & GRAY LLP
Z. Angela Guo, J.D., Ph.D.**PHONE:** (617) 951-7546**Attorney Dkt. #:** VASG-P01-002**PAGES (Including Cover Sheet):** 8**CONTENTS:** Reply Under 37 C.F. R. Section 1.111 (7 pages)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 951-7546 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

ROPES & GRAY LLP
One International Place, Boston, Massachusetts 02110
Telephone: (617) 951-7000 **Facsimile:** (617) 951-7050

RECEIVED
CENTRAL FAX CENTER

JAN 07 2009

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below.

Dated: 1/7/09 Signature: [Signature]
(Ginny Blundell)

Docket No.: VASG-P01-002
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Krasnoperov et al.

Application No.: 10/800,350

Confirmation No.: 2293

Filed: March 12, 2004

Art Unit: 1642

For: POLYPEPTIDE COMPOUNDS FOR
INHIBITING ANGIOGENESIS AND TUMOR
GROWTH

Examiner: Sean E. Aeder

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY UNDER 37 C.F.R. SECTION 1.111

Dear Sir:

This Reply is filed in response to the Office Action mailed October 7, 2008 in the above-identified application. Reconsideration and further examination are requested. Please enter the following remarks/arguments:

Remarks/Arguments begin on page 2 of this paper.